Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0NCRMF
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
WO2021044208A1 ADC AB4-2
|
|||||
| Synonyms |
WO2021044208A1 ADC AB4-2
Click to Show/Hide
|
|||||
| Organization |
LegoChem Biosciences, Inc.; ABL Bio, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 3 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Lung cancer [ICD11:2C25]
Investigative
Mantle cell lymphoma [ICD11:2A85]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-ROR1 mAb AB4
|
Antibody Info | ||||
| Antigen Name |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin F
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
WO2021044208A1_ADC AB4-2 linker
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.